您是第 10279209 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

IMR-32人神经母细胞瘤细胞 (STR鉴定)

英文名:IMR-32
货号:ZQ0398
价格:¥1750.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

IMR-32人神经母细胞瘤细胞 (STR鉴定)

¥1750.00
+

IMR-32人神经母细胞瘤细胞专用培养基

¥350.00 ¥450.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥2100 ¥2200.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

IMR-32人神经母细胞瘤细胞

货号

ZQ0398

产品介绍

IMR-32是一种人类神经母细胞瘤细胞系,来源于一名被诊断为神经母细胞瘤的儿童的肾上腺髓质,神经母细胞瘤是一种起源于神经嵴细胞的恶性肿瘤。这些细胞表现出未成熟神经细胞的特征,使它成为研究神经分化、神经母细胞瘤发病机制和神经发育过程分子机制的有价值的模型。IMR-32细胞具有很高的增殖能力,并保留合成儿茶酚胺的能力,特别是多巴胺和去甲肾上腺素,这是神经系统中必不可少的神经递质。

IMR-32细胞表现为二倍体核型,具有通常与神经母细胞瘤相关的特定染色体畸变,如MYCN癌基因扩增。这一特征使得它对神经母细胞瘤的遗传和分子驱动因素的研究特别有用,包括MYCN在肿瘤发生和进展中的作用。此外,IMR-32细胞被用于药物筛选试验,以评估针对神经母细胞瘤的潜在治疗药物的疗效和细胞毒性。然而,重要的是要注意,这些细胞仅用于体外研究目的,不适合任何治疗或体内应用。

注意事项:
(1)存在两种细胞类型。主要是小的神经母细胞样细胞和是大的透明成纤维细胞。IMR-32细胞可能堆积并成片生长。
(2)IMR-32细胞消化后需24-48小时贴壁完全,细胞培养48小时后可换液。细胞融合度80%以上即可传代。
(3))细胞贴壁性差,建议使用Corning CellBIND(3289)培养瓶进行培养。

种属

性别/年龄

男/13个月

组织

疾病

成神经细胞瘤

细胞类型

肿瘤细胞

形态学

成神经细胞

生长方式

贴壁

倍增时间

大约20~50小时 

培养基和添加剂

MEM(中乔新舟  货号:ZQ-300+10%胎牛血清(中乔新舟  货号:ZQ0500+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0398

生物安全等级

BSL-1

STR位点信息

Amelogenin: X,Y

CSF1PO: 11,12

D13S317: 9

D16S539: 8

D5S818: 11,12

D7S820: 9,10

THO1: 7,9.3

TPOX: 11

vWA: 15

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

  ***

基因表达

  ***

保藏机构

ATCC; CCL-127 BCRC; 60014 BCRJ; 0377 DSMZ; ACC-165 ECACC; 86041809

供应限制

仅供科研使用

货号

ZQ0398

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


PubMed=5459762
Tumilowicz J.J., Nichols W.W., Cholon J.J., Greene A.E.
Definition of a continuous human cell line derived from neuroblastoma.
Cancer Res. 30:2110-2118(1970)


DOI=10.1007/978-1-4757-1647-4_13
Biedler J.L.
Chromosome abnormalities in human tumor cells in culture.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975)


PubMed=62055; DOI=10.1093/jnci/57.3.683
Biedler J.L., Spengler B.A.
A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture.
J. Natl. Cancer Inst. 57:683-695(1976)


PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)


PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)


PubMed=922665; DOI=10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1
Brodeur G.M., Sekhon G., Goldstein M.N.
Chromosomal aberrations in human neuroblastomas.
Cancer 40:2256-2263(1977)



CLPUB00387

Coriell L.L., Greene A.E., Mulivor R.A.
The human genetic mutant cell repository: list of genetic variants, chromosomal aberrations and normal cell cultures submitted to the repository. 7th edition. October 1980.
(In) Institute for Medical Research (Camden, N.J.) NIH 80-2011; pp.1-254; National Institutes of Health; Bethesda (1980)



PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)


PubMed=7253718; DOI=10.1016/0047-6374(81)90027-0
Das N.K., Murphy D.G.
The National Institute on Aging repository cell cultures.
Mech. Ageing Dev. 16:1-17(1981)


PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)


PubMed=7037175
Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.
Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant.
Cancer Res. 42:1331-1336(1982)


PubMed=7139592; DOI=10.1016/0165-4608(82)90105-4
Gilbert F., Balaban G.B., Moorhead P.S., Bianchi D., Schlesinger H.R.
Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.
Cancer Genet. Cytogenet. 7:33-42(1982)


DOI=10.1016/B978-0-12-008304-6.50015-4
Biedler J.L., Meyers M.B., Spengler B.A.
Homogeneously staining regions and double minute chromosomes, prevalent cytogenetic abnormalities of human neuroblastoma cells.
(In) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York (1983)


PubMed=6401685; DOI=10.1007/BF02617989
Halton D.M., Peterson W.D. Jr., Hukku B.
Cell culture quality control by rapid isoenzymatic characterization.
In Vitro 19:16-24(1983)


PubMed=6888561; DOI=10.1038/305245a0
Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.
Nature 305:245-248(1983)


PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)


PubMed=3698005
Bregman M.D., Funk C., Fukushima M.
Inhibition of human melanoma growth by prostaglandin A, D, and J analogues.
Cancer Res. 46:2740-2744(1986)


PubMed=2535691
Ciccarone V.C., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.
Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.
Cancer Res. 49:219-225(1989)


PubMed=8221663
Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y.
Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Cancer Res. 53:5284-5288(1993)


PubMed=8490657; DOI=10.1038/ng0193-62
The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G., Gusella J.F., Bernards A.
Neurofibromatosis type 1 gene mutations in neuroblastoma.
Nat. Genet. 3:62-66(1993)


DOI=10.1016/B978-0-12-333530-2.50006-X
Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994)


PubMed=7838528
Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995)


PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4
Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.
The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
Cancer Lett. 104:183-192(1996)


PubMed=9201287
Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G., Gumbel H.O., Rabenau H.F., Kornhuber B., Doerr H.-W.
Increased efficacy of aphidicolin killing of human neuroblastoma cells in vitro by encapsulation in liposomes.
Neoplasma 44:91-95(1997)


PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7
Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R., De Paepe A., Cremer T., Speleman F.
Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Cancer Genet. Cytogenet. 97:135-142(1997)


PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5
Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R., van der Drift P., Chan A., Versteeg R., Speleman F.
Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.
Eur. J. Cancer 33:1974-1978(1997)


DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)


PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001)


PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)


PubMed=12210830; DOI=10.1002/jnr.10330
Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.
Malignant rhabdoid tumor shows incomplete neural characteristics as revealed by expression of SNARE complex.
J. Neurosci. Res. 69:642-652(2002)


PubMed=12702577
Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.
PPM1D is a potential target for 17q gain in neuroblastoma.
Cancer Res. 63:1876-1883(2003)


PubMed=15390183; DOI=10.1002/gcc.20096
Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.
Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
Genes Chromosomes Cancer 41:297-308(2004)


PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)


PubMed=16524757; DOI=10.1016/j.biocel.2006.01.007
Fry D.G., Dayton B.D., Brodjian S.J., Ogiela C., Sidorowicz H., Frost L.J., McNally T., Reilly R.M., Collins C.A.
Characterization of a neuronal cell line expressing native human melanin-concentrating hormone receptor 1 (MCHR1).
Int. J. Biochem. Cell Biol. 38:1290-1299(2006)


PubMed=16822308; DOI=10.1186/1471-2407-6-177
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)


PubMed=17974978; DOI=10.1158/0008-5472.CAN-06-4345
Xue C.-Y., Haber M., Flemming C., Marshall G.M., Lock R.B., MacKenzie K.L., Gurova K.V., Norris M.D., Gudkov A.V.
p53 determines multidrug sensitivity of childhood neuroblastoma.
Cancer Res. 67:10351-10360(2007)


PubMed=20655465; DOI=10.1016/j.cell.2010.06.004
Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010)


PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)


PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqx...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号